Fidelity Investments’s Lucid Diagnostics LUCD Stock Holding History

Fidelity Investments’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.51K	Sell	4,215 -116,354	-97%	-$125K	﹤0.01%	5032
2026 Q1	$139K	Buy	120,569 +89,611	+289%	+$114K	﹤0.01%	3661
2025 Q4	$33.7K	Buy	30,958 +30,655	+10,117%	+$34.3K	﹤0.01%	4269
2025 Q3	$306	Sell	303 -856	-74%	-$935	﹤0.01%	5125
2025 Q2	$1.33K	Buy	1,159 +604	+109%	+$780	﹤0.01%	4924
2025 Q1	$827	Buy	+555	New	+$666	﹤0.01%	4975
2022 Q3	–	Sell	-182	Closed	–	–	5202
2022 Q2	$0	Buy	+182	New	+$404	﹤0.01%	5261

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fidelity Investments's LUCD Position: Q2 2026 in Review

Fidelity Investments reduced its Lucid Diagnostics (LUCD) stake by 97% in Q2 2026, selling an estimated $125K and leaving 4,215 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #5032.

Fidelity Investments first reported a position in LUCD in Q2 2022 and has held it in 7 quarters since. The position peaked at $139K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Fidelity Investments held 4,215 shares of Lucid Diagnostics worth $4.51K as of Q2 2026.
Fidelity Investments sold 116,354 Lucid Diagnostics shares in Q2 2026, an estimated $125K.
Lucid Diagnostics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5032 holding.
Fidelity Investments first reported a position in Lucid Diagnostics in Q2 2022 and has held it in 7 quarters since.
Fidelity Investments's Lucid Diagnostics position peaked at $139K in Q1 2026.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.